BD Diagnostics has obtained a CE marking for the BD MAX MRSA assay designed to identify methicillin-resistant staphylococcus aureus (MRSA) in patients
According to the company, the system provides rapid and accurate information to allow infection control measures to be implemented faster.
"When we launched BD MAX earlier this year, our goal was to provide a next-generation molecular testing system designed to accommodate a broad range of assays that laboratories want and need," said Tom Polen, President, BD Diagnostics - Diagnostic Systems.
"This system enables laboratories to offer a broad range of molecular tests that meet both their current and future clinical needs." The dual functionality of open system and CE/IVD capabilities on the BD MAX System enables laboratories to consolidate a broad range of molecular tests on a single workstation.
This flexibility provides clinicians with the best information to make critical treatment and management decisions to improve patient care.
According to Polen, BD plans to build on the successful launch of the BD MAX MRSA Assay by developing additional assays for the BD MAX System for a broad range of disease categories.
